<?xml version="1.0" encoding="UTF-8"?>
<p id="Par36">Cutaneous melanoma originates from melanocytes [
 <xref ref-type="bibr" rid="CR1">1</xref>]. Although melanoma has a lower incidence than other types of skin cancer, melanoma is responsible for the majority of skin cancer-related deaths worldwide, and its incidence is increasing [
 <xref ref-type="bibr" rid="CR2">2</xref>, 
 <xref ref-type="bibr" rid="CR3">3</xref>]. The life expectancy of melanoma patients is mainly determined by disease stage, and patients with advanced-stage disease have a significantly worse prognosis [
 <xref ref-type="bibr" rid="CR4">4</xref>]. Since the introduction of immune checkpoint inhibitors (ICIs) and targeted therapies, the prognosis of patients with advanced (i.e. irresectable stage IIIC) and metastatic (i.e. stage IV) melanoma has improved significantly [
 <xref ref-type="bibr" rid="CR5">5</xref>–
 <xref ref-type="bibr" rid="CR7">7</xref>]. Nowadays, first-line monotherapy with the programmed cell death protein 1 (PD-1) blockers nivolumab (Opdivo®) or pembrolizumab (Keytruda®) is administered most frequently in patients with advanced and metastatic melanoma [
 <xref ref-type="bibr" rid="CR8">8</xref>–
 <xref ref-type="bibr" rid="CR10">10</xref>].
</p>
